Getinge AB (publ) (OTCMKTS:GNGBY) Sees Large Decline in Short Interest

Getinge AB (publ) (OTCMKTS:GNGBYGet Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 9,900 shares, a decrease of 12.4% from the August 31st total of 11,300 shares. Based on an average daily trading volume, of 23,700 shares, the short-interest ratio is currently 0.4 days.

Getinge AB (publ) Stock Up 0.2 %

Shares of GNGBY stock traded up $0.05 during trading hours on Monday, reaching $21.48. The company had a trading volume of 8,867 shares, compared to its average volume of 12,463. Getinge AB has a 12 month low of $16.71 and a 12 month high of $22.85. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.67 and a quick ratio of 0.98. The company has a market cap of $5.85 billion, a price-to-earnings ratio of 27.19 and a beta of 0.82. The business has a fifty day simple moving average of $20.37 and a 200-day simple moving average of $19.38.

Getinge AB (publ) (OTCMKTS:GNGBYGet Free Report) last posted its quarterly earnings results on Thursday, July 18th. The company reported $0.21 EPS for the quarter. Getinge AB (publ) had a net margin of 7.76% and a return on equity of 8.56%. The company had revenue of $776.85 million for the quarter.

About Getinge AB (publ)

(Get Free Report)

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.

Featured Articles

Receive News & Ratings for Getinge AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.